Safety considerations of biosimilars - Wikidata - awgldk - TriplyDB

Safety considerations of biosimilars

Safety considerations of biosimilars

http://www.wikidata.org/entity/Q42353230

about

Safety considerations of biosimilars

http://www.wikidata.org/entity/Q42353230

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Safety considerations of biosimilars

@en

Safety considerations of biosimilars

@en-gb

Safety considerations of biosimilars

@nl

type

label

Safety considerations of biosimilars

@en

Safety considerations of biosimilars

@en-gb

Safety considerations of biosimilars

@nl

prefLabel

Safety considerations of biosimilars

@en

Safety considerations of biosimilars

@en-gb

Safety considerations of biosimilars

@nl

P1433

Q42353230-901588C0-2759-4552-A900-F11391C416C4

P1476

Q42353230-339560C9-1F9A-4EB6-B96C-FC6B66DA7A4E

P2093

Q42353230-36671163-1341-4603-B523-C805DD1CC1E0

P2860

Q42353230-08B16CD4-C007-477C-8F51-F7D1D0986456

Q42353230-12E73703-6869-4B62-8E2E-C7235DE87D1E

Q42353230-172548C9-8CF4-4FF5-9939-F207702F17BC

Q42353230-3D1A44A3-7BE9-42F5-A775-6ADC7B0AA4A3

Q42353230-5A0D11FA-7AB9-4A45-9DF2-2A88A68FE192

Q42353230-5EB3C885-41DD-4D41-8B1B-B5B96B5A73D5

P304

Q42353230-5D777580-C7E2-46E7-ACBE-16938C9286F0

P31

Q42353230-E1C93AFA-8E4C-4CFF-BE0A-0ADDB901F4F4

Q42353230-aa37e4a0-13b9-4fc7-bc6f-a22f75c54bc6

P356

Q42353230-553C40FC-674F-43A3-BD8C-5587269F4AFB

P433

Q42353230-CB6883A1-83D4-4797-BE22-96F95AD57321

P478

Q42353230-8C5877BE-8047-46FB-8612-F86668C22DDC

P50

Q42353230-71CE4C83-56B2-41E8-BE07-D1A302C1F70B

Q42353230-8177CE1C-850B-4425-BDFD-72473A8D73F1

P577

Q42353230-7C4E2F7A-C59B-47CD-8C85-FE85B7A746F5

P698

Q42353230-1403D6F0-0433-4921-B010-FAECA4DD2A64

P932

Q42353230-B7B8A197-6CDF-498F-A012-F522E66BE09D

P356

AUSTPRESCR.2016.084

P1433

Australian Prescriber

P1476

Safety considerations of biosimilars

@en

P2093

Ross McKinnon

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.

Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey.

Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies.

P304

188-189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18773/AUSTPRESCR.2016.084

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Ross A. McKinnon

Michael B. Ward

P577

2016-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27990042

http://www.w3.org/2001/XMLSchema#string

P932

5155057

http://www.w3.org/2001/XMLSchema#string